OBJECTIVES: This study aims to analyse the risks associated with valve-in-valve procedures for treating structural valve deterioration in Mitroflow bioprostheses, as well as to determine the impact of the original Mitroflow size on the patients' long-term outcomes. METHODS: Between January 2012 and September 2019, 21 patients (61.9% males; mean age 82.4 ± 5.4 years) were treated for Mitroflow deterioration with valve-in-valve procedures (12 transapical and 9 transfemoral). RESULTS: Mean EuroSCORE I and EuroSCORE II were 28.2% ± 13.6% and 10.5% ± 6.1%, respectively. Six patients presented an indexed aortic root diameter <14 mm/m2 and 7 patients a diameter of sinus of Valsalva <30 mm. Implanted transcatheter valve sizes were 20 mm in 6 cases, 23 mm in 14 cases and 26 mm in 1 patient. A Valve Academic Research Consortium-2 complication occurred in 23.8% of cases, including 3 coronary occlusions. In-hospital mortality was 9.5%. The 20 mm transcatheter valves presented significantly higher postoperative peak and mean aortic gradients than other sizes (54.1 ± 11.3 mmHg vs 29.9 ± 9.6 mmHg, P = 0.003; and 29.3 ± 7.7 mmHg vs 17.4 ± 5.9 mmHg, P = 0.015, respectively). There were 12 cases of patient-prosthesis mismatch (57.1%) and 3 cases (14.3%) of severe patient-prosthesis mismatch. Cumulative survival was 85.7% ± 7.6% at 1 year, 74.3% ± 10% at 2 years and 37.1% ± 14.1% at 5 years. CONCLUSIONS: Valve-in-valve procedures with balloon-expandable transcatheter valves associate a high risk of coronary occlusion in patients with indexed aortic root diameter <14 mm/m2 and low coronary ostia <12 mm. Valve-in valve procedures with 20 mm balloon-expandable transcatheter valves in ≤21 mm Mitroflow bioprosthesis leave significant residual transvalvular gradients that might obscure patients' long-term outcomes.
OBJECTIVES: This study aims to analyse the risks associated with valve-in-valve procedures for treating structural valve deterioration in Mitroflow bioprostheses, as well as to determine the impact of the original Mitroflow size on the patients' long-term outcomes. METHODS: Between January 2012 and September 2019, 21 patients (61.9% males; mean age 82.4 ± 5.4 years) were treated for Mitroflow deterioration with valve-in-valve procedures (12 transapical and 9 transfemoral). RESULTS: Mean EuroSCORE I and EuroSCORE II were 28.2% ± 13.6% and 10.5% ± 6.1%, respectively. Six patients presented an indexed aortic root diameter <14 mm/m2 and 7 patients a diameter of sinus of Valsalva <30 mm. Implanted transcatheter valve sizes were 20 mm in 6 cases, 23 mm in 14 cases and 26 mm in 1 patient. A Valve Academic Research Consortium-2 complication occurred in 23.8% of cases, including 3 coronary occlusions. In-hospital mortality was 9.5%. The 20 mm transcatheter valves presented significantly higher postoperative peak and mean aortic gradients than other sizes (54.1 ± 11.3 mmHg vs 29.9 ± 9.6 mmHg, P = 0.003; and 29.3 ± 7.7 mmHg vs 17.4 ± 5.9 mmHg, P = 0.015, respectively). There were 12 cases of patient-prosthesis mismatch (57.1%) and 3 cases (14.3%) of severe patient-prosthesis mismatch. Cumulative survival was 85.7% ± 7.6% at 1 year, 74.3% ± 10% at 2 years and 37.1% ± 14.1% at 5 years. CONCLUSIONS: Valve-in-valve procedures with balloon-expandable transcatheter valves associate a high risk of coronary occlusion in patients with indexed aortic root diameter <14 mm/m2 and low coronary ostia <12 mm. Valve-in valve procedures with 20 mm balloon-expandable transcatheter valves in ≤21 mm Mitroflow bioprosthesis leave significant residual transvalvular gradients that might obscure patients' long-term outcomes.
Authors: Daniele Camboni; Andreas Holzamer; Bernhard Flörchinger; Kurt Debl; Dierk Endeman; York Zausig; Lars S Maier; Christof Schmid; Michael Hilker Journal: Ann Thorac Surg Date: 2015-02-07 Impact factor: 4.330
Authors: Victor X Mosquera; Miguel González-Barbeito; Alberto Bouzas-Mosquera; José M Herrera-Noreña; Carlos Velasco; Jorge Salgado-Fernández; Ramón Calviño-Santos; Nicolás Vázquez-González; José M Vázquez-Rodríguez; José J Cuenca-Castillo Journal: J Card Surg Date: 2018-05-22 Impact factor: 1.620
Authors: Jaffar M Khan; Adam B Greenbaum; Vasilis C Babaliaros; Toby Rogers; Marvin H Eng; Gaetano Paone; Bradley G Leshnower; Mark Reisman; Lowell Satler; Ron Waksman; Marcus Y Chen; Annette M Stine; Xin Tian; Danny Dvir; Robert J Lederman Journal: JACC Cardiovasc Interv Date: 2019-06-12 Impact factor: 11.195
Authors: Isaac Pascual; Pablo Avanzas; Daniel Hernández-Vaquero; Rocío Díaz; Raquel Del Valle; Remigio Padrón; Rebeca Lorca; Victor León; María Martín; Fernando Alfonso; César Morís Journal: Int J Cardiol Date: 2019-02-01 Impact factor: 4.164
Authors: Leonardo de Freitas Campos Guimarães; Marina Urena; Harindra C Wijeysundera; Antonio Munoz-Garcia; Vicenç Serra; Luis M Benitez; Vincent Auffret; Asim N Cheema; Ignacio J Amat-Santos; Quentin Fisher; Dominique Himbert; Bruno Garcia Del Blanco; Antonio Dager; Hervé Le Breton; Jean-Michel Paradis; Eric Dumont; Philippe Pibarot; Josep Rodés-Cabau Journal: Circ Cardiovasc Interv Date: 2018-09 Impact factor: 6.546
Authors: Henrique B Ribeiro; Josep Rodés-Cabau; Philipp Blanke; Jonathon Leipsic; Jong Kwan Park; Vinayak Bapat; Raj Makkar; Matheus Simonato; Marco Barbanti; Joachim Schofer; Sabine Bleiziffer; Azeem Latib; David Hildick-Smith; Patrizia Presbitero; Stephan Windecker; Massimo Napodano; Alfredo G Cerillo; Mohamed Abdel-Wahab; Didier Tchetche; Claudia Fiorina; Jan-Malte Sinning; Mauricio G Cohen; Mayra E Guerrero; Brian Whisenant; Fabian Nietlispach; José Honório Palma; Luis Nombela-Franco; Arend de Weger; Malek Kass; Fabio Sandoli de Brito; Pedro A Lemos; Ran Kornowski; John Webb; Danny Dvir Journal: Eur Heart J Date: 2018-02-21 Impact factor: 29.983